Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelodysplastic syndrome overview.

Razelle Kurzrock1

  • 1Department of Bioimmunotherapy, M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Seminars in Hematology
|September 6, 2002
PubMed
Summary

Myelodysplastic syndrome (MDS) is a common blood disorder in older adults. An oral farnesyltransferase inhibitor, ZARNESTRA, shows promising activity against MDS, warranting further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match.

The oncologist·2018
Same author

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2018
Same author

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

JAMA oncology·2018
Same author

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2018
Same author

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.

Cancer biology & therapy·2018
Same author

Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).

Cancer biology & therapy·2018

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Myelodysplastic syndrome (MDS) is a bone marrow disorder affecting mostly older adults.
  • Current MDS treatments lack consistent efficacy and survival benefits.
  • High toxicity and limited curative options necessitate novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the anti-MDS activity of the oral farnesyltransferase inhibitor (FTI) ZARNESTRA.
  • To explore the potential of FTIs as a treatment class for myelodysplastic syndromes.

Main Methods:

  • Phase I and II clinical studies were conducted.
  • The oral FTI ZARNESTRA (formerly R115777) was administered to patients with MDS.

Main Results:

  • ZARNESTRA demonstrated promising anti-MDS activity in early clinical trials.
  • FTIs modulate key cancer-signaling pathways relevant to MDS.

Conclusions:

  • The oral FTI ZARNESTRA shows potential for treating myelodysplastic syndrome.
  • Further investigation of FTIs in MDS is warranted due to their mechanism of action and promising early results.

Related Experiment Videos